Monopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher – Time to Buy?

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) were up 0.4% during trading on Wednesday . The company traded as high as $36.55 and last traded at $34.65. Approximately 11,648 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 358,561 shares. The stock had previously closed at $34.51.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on MNPR shares. Wall Street Zen upgraded shares of Monopar Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Piper Sandler restated an “overweight” rating and set a $76.00 target price on shares of Monopar Therapeutics in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Monopar Therapeutics in a report on Tuesday, April 1st. Finally, Jones Trading restated a “hold” rating on shares of Monopar Therapeutics in a report on Wednesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $55.33.

Monopar Therapeutics Stock Up 0.4%

The stock has a market capitalization of $211.88 million, a price-to-earnings ratio of -17.59 and a beta of 0.99. The company’s fifty day simple moving average is $36.98 and its 200 day simple moving average is $33.79.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.27. As a group, analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Insider Activity

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of the business’s stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the sale, the insider now owns 822,255 shares of the company’s stock, valued at approximately $28,778,925. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MNPR. AlphaQuest LLC bought a new stake in Monopar Therapeutics during the first quarter worth about $44,000. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the fourth quarter worth about $45,000. Gerber LLC bought a new stake in Monopar Therapeutics during the first quarter worth about $204,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics during the first quarter worth about $328,000. Finally, Jane Street Group LLC bought a new stake in Monopar Therapeutics during the first quarter worth about $377,000. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.